Novo Nordisk's real-world data indicates Wegovy 2.4 mg may outperform resmetirom in key MASH markers, though the retrospective nature of the studies limits definitive causal conclusions.
The headline data show Novo's semaglutide 2.4 mg beating resmetirom, Madrigal's MASH drug, on AST (p<0.001), HbA1c and weight at 3 and 6 months, with broadly similar triglyceride effects. Head-to-head real-world results favoring a competing GLP-1 could pressure prescribing sentiment for resmetirom. The comparison is observational and resmetirom still showed meaningful ALT reduction (-11.6 U/L at 6 months), limiting the damage.
The real-world data favor semaglutide 2.4 mg on liver enzymes, blood sugar and weight, but because the study is observational and non-randomized, it does not definitively establish superiority in causal terms.
Real-world data presented on Nov 6, 2026 at AASLD show semaglutide 2.4 mg (Wegovy) outperforming resmetirom on liver enzymes, weight (-18.9 lb vs -5.6 lb at 6 months) and HbA1c in MASH patients. This supports the MASH indication and the ongoing ESSENSE phase 3 confirmatory trial. The data are retrospective and non-randomized with acknowledged limitations, capping the upside.
Real-world studies PLATINUM-Truveta and RHODIUM-2 showed semaglutide 2.4 mg reduced liver enzymes (ALT -14.8 U/L at 6 months), body weight (-18.9 lb at 6 months) and HbA1c (-0.38 points) in MASH patients, generally outperforming resmetirom at 3 and 6 months.
No. The data are associations from retrospective, non-randomized studies; the article notes causal relationships cannot be definitively established and continued approval depends on the confirmatory ESSENSE phase 3 trial.
Novo Nordisk presented real-world data from the PLATINUM-Truveta and RHODIUM-2 studies at The Liver Meeting 2026, showing semaglutide 2.4 mg (Wegovy) associated with significant reductions in liver enzymes, body weight, and HbA1c in MASH patients. The findings, which compared semaglutide against resmetirom and non-treatment cohorts, support the ongoing ESSENCE phase 3 confirmatory trial for the drug's MASH indication.
Real-world studies PLATINUM-Truveta and RHODIUM-2 showed semaglutide 2.4 mg reduced liver enzymes, body weight, and HbA1c in MASH patients, generally outperforming resmetirom at 3 and 6 months.
The real-world data favor semaglutide 2.4 mg on liver enzymes, blood sugar and weight, but because the study is observational and non-randomized, it does not definitively establish superiority in causal terms.